Artax Biopharma
Signal active
Organization
Contact Information
Overview
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
About
Industries
Biotechnology, Health Care, Biopharma, Therapeutics
Founded
2013
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Artax Biopharma headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $12.1B in funding across 160 round(s). With a team of 1-10 employees, Artax Biopharma is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Artax Biopharma, raised $1.3M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
10
Investors
0
Lead Investors
0
Total Funding Amount
$75.8M
Details
3
Artax Biopharma has raised a total of $75.8M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | |||
| 2015 | Early Stage Venture | 10.0M | ||
| 2014 | Early Stage Venture | 2.0M |
Investors
Artax Biopharma is funded by 29 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Artax Biopharma | - | FUNDING ROUND - Artax Biopharma | 10.0M |
| Lysosomal Therapeutics | - | FUNDING ROUND - Lysosomal Therapeutics | 10.0M |
| Artax Biopharma | - | FUNDING ROUND - Artax Biopharma | 2.0M |
| Realiza Business Angels | - | FUNDING ROUND - Realiza Business Angels | 2.0M |
Recent Activity
There is no recent news or activity for this profile.